The federal Food and Drug Administration (FDA) has issued a notice requesting that public stakeholders –including patient and consumer advocacy groups, health care professionals, and scientific and academic experts– notify FDA of their intent to participate in monthly consultation meetings on the reauthorization of the Prescription Drug User Fee Act (PDUFA). When the statutory authority for PDUFA expires in September 2017, new legislation will be required for FDA to continue collecting user fees for the prescription drug program. The monthly consultation meetings FDA plans to hold are meant to ensure continuity and progress by establishing consistent stakeholder representation. Interested parties can submit notification of intention to participate by August 28, 2015 by email to: FDA anticipates that the meetings will commence in September or October 2015.